LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LENZ is expected to report earnings to rise 279.17% to -91 cents per share on March 25
Q4'23
Est.
$-0.91
Q3'23
Est.
$-0.24
Q2'23
Missed
by $5.82
Q1'23
Missed
by $2.61
Q4'22
Missed
by $2.59
The last earnings report on November 08 showed earnings per share of -23 cents, meeting the estimate of -23 cents. With 65.75K shares outstanding, the current market capitalization sits at 651.22M.